Good Thing Generics Were Elevated
So last month I
But no, there is no equivalence between PD and GD apparently. In either a pre-emptive move or a real concern that generic prescriptions now account for almost 80% of all prescriptions in the US, that announcement seems prophetic now. Prophetic or calculated based on the FDA’s early
There are a couple of issues that stand of for me in this blog that were posted on this topic from
- The FDA received final results on the efficacy issue to budeprion in August, which is quite near to the time that the Office of Generic Drugs was elevated within CDER. Prophetic or calculated?
- The determination of bioequivalence for the 300mg dose was actually never studied by Impax, and waived by FDA based on safety reasons. Rather, the data from the 150mg was extrapolated and used for its approval of bioequivalency. As we know with the generic forms of biologics or biosimilars, they aren’t equivalent, they are similar.
I envision some downstream effects from this announcement. Central to what the Forbes blogger was mentioning about the effect on patients. What I see is a general public that is either assured by a pharmacist, physician or the individual’s health plan that generics are just lower-priced copies of the original. They are “just-as-good.” But here, we see, they may not be just as good. In fact, a doctor recently told me to take a brand name of a drug because the generic may be inferior.
I think health plans and formularies may have a hard time explaining why all their customers want the “real” drug. Or we will just shoulder the costs and pay the higher amount so we can get the “real” drug. This is worse than shopping online for drugs. Because the public assumes that it’s OK. They don’t understand the minutae that is the FDA or CDER for that matter.
CDER has recognized the issue and responded by elevating the Office of Generic Drugs.
As
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025